Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vitamin C in Food: Why Do We Still Feel Deficient? - 26 Home Cleaning Administrations to Keep Your Home Unblemished
- 3Investigating the Advantages of a Bank account: A Complete Aide
- 4‘RichTok’ Influencer Becca Bloom Shows Off Custom Invitations and ‘Most Valued Possession’ from Her Viral 2025 Wedding
- 5Tremendous Spelunking: Cool Caverns All over the Planet
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- Scientists map of old Mars river basins for the 1st time. These could be great places to search for ancient life
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Why home maintenance deserves a spot in the annual health and budget plans
- Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
- 'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- The Best Competitors of the 21st Hundred years
